5.02
0.16 (3.29%)
| Previous Close | 4.86 |
| Open | 4.92 |
| Volume | 2,886,452 |
| Avg. Volume (3M) | 2,203,054 |
| Market Cap | 452,804,000 |
| Price / Earnings (Forward) | 29.41 |
| Price / Sales | 0.200 |
| Price / Book | 0.400 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 |
| Profit Margin | -12.18% |
| Operating Margin (TTM) | -4.02% |
| Diluted EPS (TTM) | -3.03 |
| Quarterly Revenue Growth (YOY) | -1.80% |
| Total Debt/Equity (MRQ) | 88.00% |
| Current Ratio (MRQ) | 1.00 |
| Operating Cash Flow (TTM) | 262.80 M |
| Levered Free Cash Flow (TTM) | 421.85 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -17.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Fortrea Holdings Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.0 |
| Average | 1.75 |
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.30% |
| % Held by Institutions | 104.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Penn Davis Mcfarland Inc | 31 Dec 2024 | 1,106,080 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Evercore ISI Group, 198.81%) | Hold |
| Median | 10.50 (109.16%) | |
| Low | 6.00 (Barclays, 19.52%) | Sell |
| Average | 10.50 (109.16%) | |
| Total | 3 Hold, 1 Sell | |
| Avg. Price @ Call | 8.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 10 Apr 2025 | 6.00 (19.52%) | Sell | 5.21 |
| 04 Mar 2025 | 12.00 (139.04%) | Hold | 10.96 | |
| Mizuho | 09 Apr 2025 | 10.00 (99.20%) | Hold | 6.45 |
| Evercore ISI Group | 04 Mar 2025 | 15.00 (198.80%) | Hold | 10.96 |
| Goldman Sachs | 04 Mar 2025 | 11.00 (119.12%) | Hold | 10.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025 |
| 15 Apr 2025 | Announcement | Fortrea Announces Date for First Quarter 2025 Financial Results and Conference Call |
| 03 Mar 2025 | Announcement | Fortrea Reports Fourth Quarter and Full-Year 2024 Results; Issues Full-Year 2025 Guidance |
| 21 Feb 2025 | Announcement | Fortrea to Add Erin L. Russell to Board of Directors |
| 20 Feb 2025 | Announcement | Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |